A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer.

about

A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer.

Item

http://www.wikidata.org/entity/Q38749030

description

2016 nî lūn-bûn

@nan

2016 թվականի օգոստոսի 30-ին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

name

A functional bioassay to deter ...... blood of patients with cancer.

@en

type

Item

label

A functional bioassay to deter ...... blood of patients with cancer.

@en

prefLabel

A functional bioassay to deter ...... blood of patients with cancer.

@en

P1476

A functional bioassay to deter ...... blood of patients with cancer

@en

P2093

Arjan W Griffioen

http://www.w3.org/2001/XMLSchema#string

Epie Boven

http://www.w3.org/2001/XMLSchema#string

Henk J Broxterman

http://www.w3.org/2001/XMLSchema#string

Henk M W Verheul

http://www.w3.org/2001/XMLSchema#string

Madelon Q Wentink

http://www.w3.org/2001/XMLSchema#string

Maudy Walraven

http://www.w3.org/2001/XMLSchema#string

Roberto Pili

http://www.w3.org/2001/XMLSchema#string

Siu W Lam

http://www.w3.org/2001/XMLSchema#string

Tanja D de Gruijl

http://www.w3.org/2001/XMLSchema#string

P2860

Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models

A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use.

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.

Platelet: transporter of vascular endothelial growth factor.

Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma.

Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs.

Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker

P2888

bjc.2016.275

P304

940-948

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2016.275

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

Hans J van der Vliet

P577

2016-08-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1051440325

http://www.w3.org/2001/XMLSchema#string

P698

27575850

http://www.w3.org/2001/XMLSchema#string

P932

5061906

http://www.w3.org/2001/XMLSchema#string